| CAS NO: | 209728-15-4 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| Cas No. | 209728-15-4 |
| 别名 | β-Hydroxypyruvic acid lithium hydrate; 3-Hydroxypyruvic acid lithium hydrate |
| 分子式 | C3H5LiO5 |
| 分子量 | 128.01 |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 半岛bd体育手机客户端 描述 | Hydroxypyruvic acid lithium hydrate (β-Hydroxypyruvic acid lithium hydrate) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid lithium hydrate is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid lithium hydrate is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway. Hydroxypyruvic acid (lithium hydrate) (intravenous injection; 100 mg/ml; slowly over 10 min) increases the 5-h urinary oxalate and glycolate excretion to 0.68% (6.56 μmol) and 0.53% (5.10 μmol) in control rats, in addition, it increases to 2.43% (23.36 μmol) and 0.79% (7.59 μmol) of the dose in the vitamin-B6-deficient rats[1]. [1]. Teerajetgul Y, et al. Oxalate synthesis from hydroxypyruvate in vitamin-B6-deficient rats.Urol Res. 2007 Aug;35(4):173-8. Epub 2007 Jun 13. |
m.cnreagent.com